On March 5, 2024 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 5-10, 2024 in San Diego, CA (Press release, Tempest Therapeutics, MAR 5, 2024, View Source [SID1234640794]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details:
Title: PPAR-α Antagonist Enhances Immunotherapy and Anti
Angiogenic Therapy to Inhibit Murine Renal Cancer
Abstract Number: 3045
Date & Time: Monday, April 8, 2024; 1:30 – 5:00 p.m. PT
Session Title: Oncogenic Transcription Factors
Location: Poster Section 18
All regular abstracts are available for viewing via AACR (Free AACR Whitepaper)’s online itinerary planner, located here.